InflaRx (NASDAQ:IFRX – Get Rating) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 205,100 shares, a decrease of 43.2% from the March 31st total of 361,000 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average trading volume of 261,100 shares, the days-to-cover ratio is presently 0.8 days.
A number of institutional investors have recently added to or reduced their stakes in the business. Walleye Capital LLC acquired a new stake in InflaRx in the fourth quarter valued at $2,525,000. Kingsview Wealth Management LLC purchased a new position in shares of InflaRx in the fourth quarter valued at $342,000. Sofinnova Investments Inc. purchased a new position in shares of InflaRx in the fourth quarter valued at $5,530,000. D. E. Shaw & Co. Inc. purchased a new position in shares of InflaRx in the fourth quarter valued at $129,000. Finally, Invesco Ltd. purchased a new position in shares of InflaRx in the fourth quarter valued at $759,000. 20.38% of the stock is owned by institutional investors.
IFRX has been the subject of several research analyst reports. Zacks Investment Research downgraded InflaRx from a “buy” rating to a “hold” rating in a report on Wednesday, January 12th. SVB Leerink decreased their price target on InflaRx from $8.00 to $6.00 and set an “outperform” rating for the company in a report on Friday, March 25th. Finally, Guggenheim downgraded InflaRx from a “buy” rating to a “neutral” rating in a report on Monday, February 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $7.13.
InflaRx (NASDAQ:IFRX – Get Rating) last released its earnings results on Thursday, March 24th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.10). As a group, equities analysts predict that InflaRx will post -1.52 EPS for the current year.
InflaRx Company Profile (Get Rating)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.
- Get a free copy of the StockNews.com research report on InflaRx (IFRX)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.